Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
Articolo
Data di Pubblicazione:
2020
Citazione:
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study / Butzkueven, H., Licata, S., Jeffery, D., Arnold, D.L., Filippi, M., Geurts, J.J., Santra, S., Campbell, N., Ho, P.. - In: BMJ OPEN. - ISSN 2044-6055. - 10:10(2020). [10.1136/bmjopen-2020-038861]
Abstract:
To directly compare the efficacy of natalizumab and fingolimod in patients with active relapsing-remitting multiple sclerosis.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
clinical trials; multiple sclerosis; neurology
Elenco autori:
Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen Jg; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran
Link alla scheda completa:
Pubblicato in: